mk 767 and bezafibrate
mk 767 has been researched along with bezafibrate in 6 studies
Compound Research Comparison
| Studies (mk 767) | Trials (mk 767) | Recent Studies (post-2010) (mk 767) | Studies (bezafibrate) | Trials (bezafibrate) | Recent Studies (post-2010) (bezafibrate) |
|---|---|---|---|---|---|
| 32 | 0 | 10 | 1,335 | 267 | 324 |
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Awano, K; Ide, T; Miyachi, H; Murakami, K; Nomura, M; Takahashi, Y; Tanase, T; Tsunoda, M | 1 |
| Ide, T; Miyachi, H; Murakami, K; Nomura, M; Suzuki, M; Tanase, T; Tsunoda, M; Uchiki, H | 1 |
| Henke, BR | 1 |
| Fujita, H; Hirose, H; Kawai, T; Miyashita, K; Ogawa, T; Saruta, T; Seto, Y; Ukeda, K; Yajima, K; Yamada, T; Yamamoto, Y | 1 |
| Narce, M; Poisson, JP | 1 |
Reviews
2 review(s) available for mk 767 and bezafibrate
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Other Studies
4 other study(ies) available for mk 767 and bezafibrate
| Article | Year |
|---|---|
Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators.
Topics: Animals; COS Cells; Drug Design; Drug Evaluation, Preclinical; Genes, Reporter; Humans; Phenylpropionates; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors; Transcriptional Activation; Transfection | 2002 |
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
Topics: Animals; CHO Cells; Cholesterol; Cricetinae; Fatty Acids, Nonesterified; Humans; Male; Models, Molecular; Phenylpropionates; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transcriptional Activation; Transfection | 2003 |
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
Topics: Animals; Bezafibrate; Body Weight; Diabetes Mellitus; Drug Therapy, Combination; Glucose; Glucose Transporter Type 2; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monosaccharide Transport Proteins; Pancreas; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |